List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals or Antidotes for Food-Producing Animals; Request for Nominations

A veterinary professional or pet owner suggests including Gabapentin/Trazodone as a compounded medication for pre-operative anxiety in pets. They argue that a combined product would improve compliance and reduce stress in clinic settings.

The commenter, likely a veterinarian or animal health professional, argues that GS-441524 should be added to the list of bulk drug substances for compounding. They state that because the drug is life-saving for treating feline infectious peritonitis and currently requires time-consuming external sourcing, its inclusion would prevent fatal delays in treatment for nonfood-producing animals.

The American Association of Feline Practitioners (AAFP) and the American Veterinary Medical Association (AVMA) are submitting nominations to add GC 376 and GS-441524 to the list of bulk drug substances for compounding office stock drugs. They argue that these substances are necessary for the urgent treatment of Feline Infectious Peritonitis (FIP) due to limited access to approved alternatives and the need for immediate treatment to prevent animal suffering.

A veterinary professional (implied by the context of treating patients and prescribing medication) argues that sucralfate should be added to the list of bulk drug substances for compounding. They state that the current requirement to script the product causes delays in emergency care and that the powder formulation is preferred by both owners and animals.

A veterinary professional argues that injectable methocarbamol should be included on the list of bulk drug substances for compounding. They state that the drug is necessary for treating pyrethrin toxicity in pets, particularly for low-income clients, and that current costs and ordering restrictions are prohibitive.

An individual, likely a veterinarian or equine practitioner, is requesting the inclusion of phenylbutazone on the list of bulk drug substances for compounding. They argue that the current FDA-approved product has flavor and volume issues that hinder effective pain management for many horses, and that compounding allows for necessary adjustments to flavor and dosage.

An equine veterinarian is requesting that phenylbutazone be added to the list of bulk drug substances for compounding office stock. She argues that immediate access to various formulations of this medication is essential for the timely treatment of sick horses, especially since the commercial paste is currently unavailable.

An individual argues that certain medications need to be included in the list of bulk drug substances for compounding to ensure pets receive correct dosages and affordable treatment options. They emphasize that veterinary clinics require immediate access to these medications for urgent care, which is not feasible if they cannot keep them in stock.

A veterinary professional (implied by the context of clinical practice) argues that the proposed action would hinder the ability of clinics to provide immediate, safe treatment for small animals. They advocate for the inclusion of certain medications in the list to allow for the sale of compounded smaller dosages, which are necessary for patient safety and comfort.

A veterinary professional (implied by the clinical context) argues that access to compounded medications is essential for treating various diseases in dogs and cats. They highlight that compounded options are often necessary when commercially available medications are unsuitable due to size or administration difficulties.